COMPANY PROFILE // THE 014 REPORT
Ocugen, Inc.
OCGN (Nasdaq) · Formerly: HISTOGENICS CORP
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberLEI 549300JVNUI9CXWJLR09 registration status is LAPSED (last update 2026-08-12): the legal-entity record has not been renewed.
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-06-03: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-07-01 and 1 more time (last 24 months).
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Ocugen, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Malvern, PA; listed as OCGN (Nasdaq).[source] It reported revenue of $4.4 million for the fiscal year ended 2025-12-31.[source] It has filed 64 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-10.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., STATE STREET CORP, VANGUARD CAPITAL MANAGEMENT LLC (as of 2026-06-30).[source] Seraphix flags 3 items from these records: 8-K Item 3.01 filed; 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-06-03; LEI 549300JVNUI9CXWJLR09 registration status is LAPSED (last update 2026-08-12).[source]
- red0
- amber3
- info1
- BlackRock, Inc.$41.3M
- STATE STREET CORP$32.8M
- VANGUARD CAPITAL MANAGEMENT LLC$22.0M
- MILLENNIUM MANAGEMENT LLC$21.3M
- GEODE CAPITAL MANAGEMENT, LLC$13.6M
- RTW INVESTMENTS, LP$10.2M
- UBS Group AG$7.9M
- Ikarian Capital, LLC$6.1M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Johnson-Greene Treerita Essalima · Chief Financial Officer (Officer) · latest Form 3 2026-03-05 · filing · LinkedIn search
- Musunuri Shankar · Chief Executive Officer (Director,Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Ramachandran Ramesh · Chief Accounting Officer (Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Castillo Kirsten · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- Chandrasekhar Satishchandran · Director · latest Form 3/A 2025-06-12 · filing · LinkedIn search
- Coleman Blaise · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- Kompella Uday · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- Zhang Junge · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Goodwin Procter Llp GOODWIN PROCTER LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-04
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001372299 | source |
| LEI | 549300JVNUI9CXWJLR09 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2016-06-25 · in -3,800 days · LEI next renewal (549300JVNUI9CXWJLR09)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-10 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-11-06 filing DEFA14A · SEC EDGAR
- 2026-11-06 filing DEFA14A · SEC EDGAR
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-15 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-15 filing 8-K items 1.01,7.01,8.01,9.01 · SEC EDGAR
- 2026-10-09 filing 144 · SEC EDGAR
- 2026-10-06 filing 8-K items 5.07 · SEC EDGAR
- 2026-09-23 filing 8-K items 5.07 · SEC EDGAR
- 2026-09-09 filing 144 · SEC EDGAR
- 2026-09-08 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-08-14 filing DEFA14A · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-30 filing DEFA14A · SEC EDGAR
- 2026-07-30 filing Proxy statement · SEC EDGAR
- 2026-07-20 filing PRE 14A · SEC EDGAR
- 2026-07-13 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-11 filing 8-K items 5.07,8.01 · SEC EDGAR
- 2026-06-03 officer change 8-K items 5.02 · SEC EDGAR
- 2026-05-14 officer change 8-K items 5.02,8.01 · SEC EDGAR
- 2026-05-14 filing 8-K items 2.03,3.02,7.01,9.01 · SEC EDGAR
- 2026-05-08 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 1.01,1.02,2.02,2.03,3.02,9.01 · SEC EDGAR
- 2026-05-05 filing 8-K items 2.02,8.01,9.01 · SEC EDGAR
- 2026-05-04 filing 8-K items 2.02,7.01,8.01,9.01 · SEC EDGAR
- 2026-04-28 filing DEFA14A · SEC EDGAR
- 2026-04-28 filing ARS · SEC EDGAR
- 2026-04-28 filing Proxy statement · SEC EDGAR
170 earlier entries
- 2026-04-20 filing PRER14A
- 2026-04-17 filing PRE 14A
- 2026-03-27 filing 8-K items 7.01,9.01
- 2026-03-24 filing 8-K items 7.01,9.01
- 2026-03-20 filing 8-K items 8.01
- 2026-03-05 insider First Form 3/4/5 on record for Johnson-Greene Treerita Essalima (Chief Financial Officer)
- 2026-03-04 filing S-8
- 2026-03-04 filing Annual report (10-K)
- 2026-03-04 filing 8-K items 8.01,9.01
- 2026-03-04 filing 8-K items 2.02,9.01
- 2026-02-09 officer change 8-K items 5.02
- 2026-01-23 filing 8-K items 7.01,8.01,9.01
- 2026-01-21 filing 8-K items 1.01,8.01,9.01
- 2026-01-21 filing 424B5
- 2026-01-15 filing 8-K items 8.01,9.01
- 2026-01-06 insider First Form 3/4/5 on record for Musunuri Shankar (Chief Executive Officer)
- 2026-01-06 insider First Form 3/4/5 on record for Ramachandran Ramesh (Chief Accounting Officer)
- 2025-12-18 officer change 8-K items 5.02
- 2025-11-05 filing Quarterly report (10-Q)
- 2025-11-05 filing 8-K items 2.02,9.01
- 2025-09-18 filing 8-K items 1.02
- 2025-09-16 filing 8-K items 1.01
- 2025-09-05 filing 8-K items 1.01
- 2025-08-11 filing 8-K items 1.01,7.01,9.01
- 2025-08-11 filing 424B5
- 2025-08-04 filing Quarterly report (10-Q)
- 2025-08-01 filing 8-K items 2.02,9.01
- 2025-07-30 filing 8-K items 8.01
- 2025-07-29 filing 8-K items 8.01
- 2025-07-09 filing 144
- 2025-07-01 filing 8-K items 3.01
- 2025-06-23 filing 8-K items 1.01,7.01,9.01
- 2025-06-17 filing 8-K items 8.01,9.01
- 2025-06-12 filing 3/A
- 2025-06-11 filing 144
- 2025-06-09 insider First Form 3/4/5 on record for Castillo Kirsten (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Chandrasekhar Satishchandran (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Coleman Blaise (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Kompella Uday (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Zhang Junge (Director)
- 2025-06-05 filing 8-K items 5.07,8.01,9.01
- 2025-05-09 filing 8-K items 2.02,9.01
- 2025-05-09 filing Quarterly report (10-Q)
- 2025-05-01 filing 8-K items 7.01,9.01
- 2025-04-25 filing ARS
- 2025-04-25 filing DEFA14A
- 2025-04-25 filing Proxy statement
- 2025-04-25 officer change 8-K items 5.02
- 2025-04-04 filing 8-K items 8.01,9.01
- 2025-03-05 filing S-8
- 2025-03-05 filing Annual report (10-K)
- 2025-03-05 filing 8-K items 2.02,9.01
- 2025-03-03 filing 8-K items 8.01,9.01
- 2025-02-13 filing EFFECT
- 2025-02-12 filing 8-K items 8.01,9.01
- 2025-02-11 filing CORRESP
- 2025-02-07 filing 8-K/A items 1.01,2.03,3.02,8.01,9.01
- 2025-02-06 filing UPLOAD
- 2025-01-31 filing S-3
- 2025-01-29 filing 8-K items 8.01,9.01
- 2025-01-03 filing 8-K items 3.01
- 2024-12-03 filing 8-K items 8.01,9.01
- 2024-11-15 officer change 8-K items 5.02
- 2024-11-14 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 7.01,9.01
- 2024-11-08 filing 8-K items 1.01,2.03,3.02,8.01,9.01
- 2024-11-08 filing 8-K items 2.02,9.01
- 2024-08-16 filing 144
- 2024-08-13 filing 8-K items 8.01,9.01
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-05 filing 8-K items 8.01,9.01
- 2024-08-01 filing 424B5
- 2024-08-01 filing 8-K items 1.01,8.01,9.01
- 2024-07-31 filing 424B5
- 2024-07-08 filing 8-K items 4.01,9.01
- 2024-06-28 filing 8-K items 5.07
- 2024-06-18 filing DEFA14A
- 2024-06-06 filing 8-K items 4.01,9.01
- 2024-05-28 filing ARS
- 2024-05-28 filing Proxy statement
- 2024-05-17 filing PRE 14A
- 2024-05-14 filing 8-K items 2.02,9.01
- 2024-05-14 filing Quarterly report (10-Q)
- 2024-05-10 filing 8-A12G
- 2024-05-10 filing 8-K items 3.03,5.03,9.01
- 2024-05-01 filing EFFECT
- 2024-04-29 filing CORRESP
- 2024-04-29 filing 10-K/A
- 2024-04-29 filing 8-K items 7.01
- 2024-04-25 filing UPLOAD
- 2024-04-18 filing S-3
- 2024-04-18 filing S-8
- 2024-04-16 filing Annual report (10-K)
- 2024-04-08 filing 8-K items 8.01,9.01
- 2024-04-02 filing 8-K items 2.02,9.01
- 2024-04-01 filing 8-K items 4.02,8.01
- 2024-04-01 filing NT 10-K
- 2024-03-21 filing 8-K items 7.01
- 2024-03-20 officer change 8-K items 5.02,5.03,9.01
- 2024-03-18 filing 8-K items 7.01,8.01,9.01
- 2024-02-21 filing 8-K items 7.01,9.01
- 2024-01-08 officer change 8-K items 5.02,9.01
- 2023-12-22 filing 8-K items 8.01,9.01
- 2023-11-09 filing 8-K items 8.01,9.01
- 2023-11-09 filing 8-K items 2.02,9.01
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 3.01
- 2023-10-12 filing UPLOAD
- 2023-10-10 filing 8-K items 8.01,9.01
- 2023-10-04 filing CORRESP
- 2023-09-19 officer change 8-K items 5.02
- 2023-09-19 filing UPLOAD
- 2023-09-13 filing 8-K items 8.01,9.01
- 2023-08-22 filing 8-K items 2.02,9.01
- 2023-08-21 filing 8-K items 2.02,9.01
- 2023-08-21 filing Quarterly report (10-Q)
- 2023-08-15 filing NT 10-Q
- 2023-08-15 officer change 8-K items 5.02
- 2023-06-27 filing 8-K items 5.07
- 2023-06-21 filing DEFA14A
- 2023-06-20 filing DEFA14A
- 2023-06-09 filing DEFA14A
- 2023-06-05 filing 8-K items 8.01,9.01
- 2023-05-30 filing DEFA14A
- 2023-05-25 filing 8-K items 1.01,9.01
- 2023-05-25 filing 424B5
- 2023-05-24 filing DEFA14A
- 2023-05-23 filing 424B5
- 2023-05-22 filing DEFA14A
- 2023-05-17 filing DEFA14A
- 2023-05-15 filing DEFA14A
- 2023-05-11 filing DEFA14A
- 2023-05-08 filing DEFA14A
- 2023-05-05 filing Quarterly report (10-Q)
- 2023-05-05 filing 8-K items 8.01,9.01
- 2023-05-05 filing 8-K items 2.02,3.01,9.01
- 2023-04-21 filing EFFECT
- 2023-04-20 filing ARS
- 2023-04-20 filing Proxy statement
- 2023-04-14 filing 8-K items 8.01,9.01
- 2023-03-13 filing 8-K items 8.01,9.01
- 2023-03-10 officer change 8-K items 5.02
- 2023-03-06 officer change 8-K items 5.02,8.01
- 2023-02-28 filing S-8
- 2023-02-28 filing S-8
- 2023-02-28 filing POS AM
- 2023-02-28 filing Annual report (10-K)
- 2023-02-28 filing 8-K items 2.02,9.01
- 2023-02-28 filing POSASR
- 2023-02-06 filing 8-K items 8.01,9.01
- 2023-01-09 filing 8-K items 8.01,9.01
- 2023-01-09 filing 8-K items 8.01,9.01
- 2022-12-16 filing 8-K items 8.01,9.01
- 2022-11-08 filing 8-K items 8.01,9.01
- 2022-11-08 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 2.02,9.01
- 2022-11-01 filing 8-K items 7.01,9.01
- 2022-09-28 filing 8-K items 1.01
- 2022-09-14 filing 8-K items 8.01,9.01
- 2022-08-26 filing 8-K items 8.01,9.01
- 2022-08-17 filing 8-K items 8.01,9.01
- 2022-08-16 filing 8-K items 8.01,9.01
- 2022-08-05 filing Quarterly report (10-Q)
- 2022-08-05 filing 8-K items 2.02,9.01
- 2022-06-10 filing 424B5
- 2022-06-10 filing 8-K items 1.01,9.01
- 2022-06-07 filing 8-K items 5.07
- 2022-06-01 filing DEFA14A
- 2022-05-26 filing DEFA14A
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-10 (within 30 days) 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-06 (within 30 days) DEFA14A filed
- 2026-11-06 (within 30 days) DEFA14A filed
- 2026-11-04 (within 30 days) 10-Q filed
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-15 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-15 (older) 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-06 (older) 8-K filed: Item 5.07 shareholder vote
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:OCGN The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above; 2 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1372299 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | OCGN / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300JVNUI9CXWJLR09 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300JVNUI9CXWJLR09) | GLEIF |
| CUSIP | 67577C105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001372299 | SEC EDGAR |
former name (shown apart, not merged) (2)
- former nameHistogenics Corporation · ClinicalTrials.gov
- former nameHISTOGENICS CORP · State licences
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $4,413,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-19 10:54 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$67,846,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-19 10:54 UTC | Report an error |
| Total assets (at 2025-12-31) | $43,516,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-19 10:54 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$12,166,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-19 10:54 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $18,887,000 | 2025-12-31 | 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | as filed | 2026-11-19 10:54 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 10:54 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 10:54 UTC | Report an error |
| State of incorporation | DE | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 10:54 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 10:54 UTC | Report an error |
| Business address | 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 10:54 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 10:54 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$56,964,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-19 10:54 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $185,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-19 10:54 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $27,542,000 | 2025-12-31 | 10-K, XBRL LongTermDebtNoncurrent | as filed | 2026-11-19 10:54 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $4,352,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-19 10:54 UTC | Report an error |
| Form D total offering amount (D filed 2020-05-07) | $395 | 2020-05-07 | D | as filed | 2026-11-19 10:54 UTC | Report an error |
| Form D total amount sold (D filed 2020-05-07) | $395 | 2020-05-07 | D | as filed | 2026-11-19 10:54 UTC | Report an error |
| Form D industry group | Biotechnology | 2020-05-07 | D | as filed | 2026-11-19 10:54 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2020-05-07 | D | as filed | 2026-11-19 10:54 UTC | Report an error |
| Form D date of first sale | 2020-04-22 | 2020-05-07 | D | as filed | 2026-11-19 10:54 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001628280-26-069835
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $1,951,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001628280-26-069835 | 2026-11-19 10:54 UTC | Report an error |
| Net income (loss) | -$3,598,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001628280-26-069835 | 2026-11-19 10:54 UTC | Report an error |
| Interest expense | $3,090,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001628280-26-069835 | 2026-11-19 10:54 UTC | Report an error |
| Cash and cash equivalents | $24,632,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001628280-26-069835 | 2026-11-19 10:54 UTC | Report an error |
| Contract liabilities, noncurrent (from an earlier report) | $800,000 | at 2025-12-31 | 10-K | 2026-03-04 | 0001628280-26-014435 | 2026-11-19 10:54 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $16,000,000 | at 2026-03-31 | 10-Q | 2026-05-08 | 0001628280-26-032454 | 2026-11-19 10:54 UTC | Report an error |
| Debt due in year 2 (from an earlier report) | $13,750,000 | at 2026-03-31 | 10-Q | 2026-05-08 | 0001628280-26-032454 | 2026-11-19 10:54 UTC | Report an error |
| Debt due in year 3 (from an earlier report) | $500,000 | at 2026-03-31 | 10-Q | 2026-05-08 | 0001628280-26-032454 | 2026-11-19 10:54 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-10 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-06 Filing DEFA14A filed
- 2026-11-06 Filing DEFA14A filed
- 2026-11-04 Filing 10-Q filed
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-15 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-15 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-06 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-09-23 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-09-08 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-14 Filing DEFA14A filed
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-30 Filing DEFA14A filed (DEFA 14A)
- 2026-07-30 Filing DEF 14A filed
- 2026-07-20 Filing PRE 14A filed
- 2026-07-13 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-11 Filing 8-K filed: Item 5.07 shareholder vote; Item 8.01 other event
- 2026-06-03 Filing 8-K filed: Item 5.02 officer or director change
- 2026-05-14 Filing 8-K filed: Item 5.02 officer or director change; Item 8.01 other event
- 2026-05-14 Filing 8-K filed: Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-08 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 1.01 material agreement; Item 1.02 agreement terminated; Item 2.02 results of operations; Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-05-05 Filing 8-K filed: Item 2.02 results of operations; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-10 8-K Item 1.01, Entry Into a Material Definitive Agreement
On November 10, 2026, Ocugen, Inc. (the “Company” or “Ocugen”) entered into an Exclusive License Agreement (the “License Agreement”) with Celairis Therapeutics Holdings Pty Ltd (“Celairis”), pursuant to which Celairis was granted an exclusive, non-sublicensable, royalty-bearing license to (i) import, export, distribute, use, have used, keep, sell, have sold, or offer for sale, including to research, develop, commercialize, register, modify, enhance, improve, or otherwise exploit OCU400 (the “licensed product”) in Australia, Singapore, New Zealand, Malaysia, Thailand, Republic of the Philippines, Vietnam and Indonesia (the “Territory”) and (ii) to use the trademark selected by Ocugen in the… the 8-K · retrieved 2026-11-19 10:54 UTC - 2026-11-10 8-K Item 7.01, Regulation FD Disclosure
On November 10, 2026, the Company issued a press release announcing the execution of the License Agreement, attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as may be expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-19 10:54 UTC - 2026-11-04 8-K Item 2.02, Results of Operations and Financial Condition
On November 4, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended September 30, 2026. The Company has scheduled a conference call and webcast for 8:30 a.m. Eastern Time on November 4, 2026, to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be posted on the Company's website at www.ocugen.com. Copies of the press release and presentation materials are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K (this “Report”) and incorporated herein by… the 8-K · retrieved 2026-11-19 10:54 UTC - 2026-10-15 8-K Item 7.01
Regulation FD Disclosure. Attached as Exhibit 99.1 and incorporated herein by reference is a presentation that Ocugen, Inc. (the “Company” or “Ocugen”) will post on its website on October 15, 2026 and may use from time to time in presentations or discussions with investors, analysts, and other parties. The information disclosed under Item 7.01 of this Current Report on Form 8-K (the “Report”), including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any Company… the 8-K · retrieved 2026-11-19 10:54 UTC - 2026-10-15 8-K Item 1.01, Entry Into a Material Definitive Agreement
On October 13, 2026, Ocugen, Inc. (the “Company” or “Ocugen”) entered into an Exclusive License Agreement (the “License Agreement”) with Roots Pharmaceutical Company WLL (“Roots”), pursuant to which Roots was granted an exclusive, non-sublicensable, royalty-bearing license to (i) make, have made, manufacture, import, export, distribute, use, have used, keep, sell, have sold, or offer for sale, including to research, develop, commercialize, register, modify, enhance, improve, or otherwise exploit OCU400 (the “licensed product”)—Ocugen’s novel modifier gene therapy for retinitis pigmentosa (“RP”) in certain countries in the Middle East and North Africa (“the Territory”) and (ii) to use the… the 8-K · retrieved 2026-11-19 10:54 UTC - 2026-10-15 8-K Item 7.01, Regulation FD Disclosure
On October 14, 2026, the Company issued a press release announcing the execution of the License Agreement. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as may be expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-19 10:54 UTC - 2026-10-15 8-K Item 8.01, Other Events
On October 14, 2026, the Board of Directors (the “Board”) of the Company determined to postpone the Special Meeting of Stockholders of the Company (the “Special Meeting”), which was previously adjourned to October 26, 2026, solely with respect to the proposal to approve the adoption of an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock, par value $0.01 per share, by 250,000,000 shares (“Proposal 1”). The Special Meeting is postponed in order to provide additional time for stockholders to consider and vote on Proposal 1. The Special Meeting will be held on Tuesday, December 22, 2026… the 8-K · retrieved 2026-11-19 10:54 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $41,314,488 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 2 | STATE STREET CORP | $32,848,040 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $21,990,075 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 4 | MILLENNIUM MANAGEMENT LLC | $21,333,176 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | $13,576,029 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 6 | RTW INVESTMENTS, LP | $10,199,999 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 7 | UBS Group AG | $7,921,587 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 8 | Ikarian Capital, LLC | $6,063,348 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 9 | GMT Capital Corp | $5,363,259 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
| 10 | MARSHALL WACE, LLP | $5,217,694 | 2026-06-30 | SEC 13F filing | 2026-11-19 10:54 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- OCUGEN, INC. · LEI 549300JVNUI9CXWJLR09 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1372299.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001372299. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.